Vaxil Bio Ltd.
TSXV: VXL.V0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange Ventures
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gadi Levin
- Headquarters
- Toronto, Canada
- IPO year
- 2010
- Market cap
- CA$726.0K
- Website
- https://www.vaxil-bio.com
Loading VXL…
Loading profile data…Frequently asked questions about VXL
What does Vaxil Bio Ltd. (VXL.V) do?
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a c...
Where does VXL.V trade?
Vaxil Bio Ltd. (VXL.V) trades on the Toronto Stock Exchange Ventures.
What sector is VXL.V in?
Vaxil Bio Ltd. (VXL.V) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vaxil Bio Ltd.?
Gadi Levin is the chief executive officer of Vaxil Bio Ltd. (VXL.V).
Where is Vaxil Bio Ltd. headquartered?
Vaxil Bio Ltd. is headquartered in Canada.
Does VXL.V pay a dividend?
Vaxil Bio Ltd. (VXL.V) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VXL.V go public?
Vaxil Bio Ltd. (VXL.V) completed its initial public offering in 2010.